Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SSY Group ( (HK:2005) ) has issued an update.
SSY Group Limited has secured selection for 45 of its pharmaceutical products in the latest renewal round of China’s National Centralised Medicines Procurement, covering the first to eighth procurement batches. The winning products span major therapeutic areas such as anti-infection, cardiovascular, respiratory, digestive and nervous system drugs.
Inclusion in the national procurement programme is expected to positively influence SSY Group’s business by supporting volume growth and strengthening its competitive position in China’s public healthcare market. The announcement signals continued integration of the company’s product portfolio into China’s centralised drug purchasing system, which is a key channel for hospital drug supply and pricing in the country.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a China-focused pharmaceutical group listed in Hong Kong, engaged in the development, production and sale of a broad portfolio of medicines. Its products span key therapeutic areas including anti-infection, cardiovascular, respiratory, digestive and nervous system treatments, serving the hospital and broader healthcare market.
Average Trading Volume: 4,871,828
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.76B
For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.